Skip to main content

Table 2 Rates and reasons for discontinuation

From: Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

  Etanercept cohort Adalimumab cohort Tocilizumab cohort Adalimumab versus etanercepta Tocilizumab versus etanercepta Tocilizumab versus adalimumaba
n = 419 n = 236 n = 74 OR (95% CI); p value OR (95% CI); p value OR (95% CI); p value
Discontinuations, n (%) 207 (49.4) 142 (60.4) 23 (31.1) 1.57 (1.03; 2.41); 0.037 0.20 (0.09; 0.45); <0.001 0.13 (0.06; 0.29); <0.001
Inefficacy, n (%) 50 (11.9) 52 (22.0) 9 (12.2) 1.65 (0.88; 3.08); 0.118 0.34 (0.11; 1.00); 0.050 0.20 (0.07; 0.60); 0.004
Remission, n (%) 54 (12.9) 22 (9.3) 2 (2.7) 0.78 (0.43; 1.40); 0.404 0.12 (0.02; 0.79); 0.027 0.16 (0.02; 1.05); 0.056
Intolerance, n (%) 15 (3.6) 15 (6.4) 2 (2.7) 2.28 (1.03; 5.04); 0.042 0.84 (0.18; 4.01); 0.826 0.37 (0.08; 1.79); 0.216
 Details Hypersensitivity (5), uveitis (3), vasculitis (1), Infections (4)b Impetigo (1)    
Lymphoma (1) Hypersensitivity (3) Neutropenia (1)    
Elevated transaminases (1), neuro-psychiatric (4)b Pustulosis (1), neuro-psychiatric (5)b   0.2 5  
Others*, n (%) 88 (16.0) 53 (22.4) 10 (13.4) 1.21 (0.74; 1.96); 0.443 0.27 (0.10; 0.72); 0.009 0.22 (0.08; 0.60); 0.003
  1. aAnalyses weighted by an inverse probability of treatment estimated by a generalized propensity score. bInfections included pneumonia and soft tissue infections; Neuropsychiatric included headache, nausea, aggressiveness, anxiety, and vertigo. beta regression coefficient for continuous variables, CI confidence interval, OR odds ratio for categorical variable